Medtronic (MDT) Tops Q2 EPS by 3c, Maintains FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Medtronic, Inc. (MDT) PT Lowered to $142 at Guggenheim
November 24, 2021 8:05 AM ESTGuggenheim analyst Chris Pasquale lowered the price target on Medtronic, Inc. (NYSE: MDT) to $142.00 (from $148.00) while maintaining a Buy rating.
The analyst commented, "MDT reported FY2Q22 revenue below Consensus estimates, though relatively in-line with weakened sentiment, in our view, while adj.... More
Medtronic, Inc. (MDT) PT Lowered to $140 at Stifel
November 23, 2021 5:49 PM ESTStifel analyst Rick Wise lowered the price target on Medtronic, Inc. (NYSE: MDT) to $140.00 (from $145.00) while maintaining a Buy rating following earnings.
The analyst commented, "We were hopeful that Medtronics F2Q22 (Oct.) would reflect more-visible US procedure volume recovery/improvements. This... More
Medtronic, Inc. (MDT) PT Lowered to $145 at Needham & Company
November 23, 2021 1:27 PM ESTNeedham & Company analyst Michael Matson lowered the price target on Medtronic, Inc. (NYSE: MDT) to $145.00 (from $152.00) while maintaining a Buy rating.
The analyst commented, "MDT's F2Q22 revenue missed consensus while EPS beat consensus and organic revenue growth slowed to 2.2% from 19.0% in... More
